Volume 17, Issue 1 (8-2023)                   Qom Univ Med Sci J 2023, 17(1): 569-583 | Back to browse issues page

Ethics code: IR.IAU.NAJAFABAD.REC.1398.125


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Najafi S, Moshtaghie A A, Hassanzadeh F, Nayeri H, Jafari E. Synthesis of New Atorvastatin Derivatives and Assessing Their Effect on Liver and Kidney Serum Parameters, Function, and Histology in Rabbits. Qom Univ Med Sci J 2023; 17 (1) : 2866.1
URL: http://journal.muq.ac.ir/article-1-3716-en.html
1- Department of Biochemistry, Faculty of Basic Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
2- Department of Biochemistry, Faculty of Basic Sciences, Falavarjan Branch, Islamic Azad University, Isfahan, Iran. , moshtaghie@pharm.mui.ac.ir
3- Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
4- Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
Full-Text [PDF 5608 kb]   (477 Downloads)     |   Abstract (HTML)  (1147 Views)
Full-Text:   (707 Views)
Introduction
High cholesterol level is a risk factor for coronary artery disease. Hyperlipidemia is a risk factor for fatty infiltration of the liver that can lead to cirrhosis and liver failure [4]. Hyperlipidemia plays an important role in the progression of kidney damage by causing fat disorders in the kidney. The occurrence of chronic kidney diseases is related to the increased plasma triglyceride and low-density lipoprotein (LDL) cholesterol levels and decreased high-density lipoprotein (HDL) cholesterol level.
Statins, as the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are often used as cholesterol-lowering drugs to prevent cardiovascular diseases. In this study, we aim to assess the effects of new atorvastatin derivatives on serum parameters, kidney and liver functions, and liver and kidney histology.
Methods
In this experimental study, all lab-grade chemicals were obtained from Sigma factory (St. Louis, MO, USA). Laboratory kits for measuring liver enzymes including serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) and alanine aminotransferase (ALP), were prepared from Pars Azmoun Company in Iran. Serum levels of triglycerides (TG), HDL, and LDL were also analyzed using laboratory kits from Pars Azmoun Company and an autoanalyzer (Biolis 24i, Tokyo, Japan). Atorvastatin derivatives S1, S2, and S3 were synthesized by acylation of the benzene ring of atorvastatin. The animals were New Zealand male rabbits, aged 4-6 weeks, with an initial weight of 1.7-2 kg. They were purchased from the Karaj Serum Factory in Iran and transferred to the animal house of Islamic Azad University, Falavarjan Branch. Rabbits received a high-fat diet (HFD) containing cholesterol powder, rapeseed oil, and a standard laboratory diet for 30 days. To investigate the effect of the drug on the liver and kidney tissue of rabbits, liver and kidney samples were fixed in 10% formalin at room temperature for further histological examination. One-way ANOVA was used to examine the significant differences between the groups, followed by the least significant difference (LSD) post hoc test and Duncan’s test to examine the significant differences in each group. Graphs were drawn in GraphPad Prism software, version n 9. All clinical tests were repeated three times for each group. Differences were considered statistically significant when P<0.05.
Results
To assess the effect of compound S3 on the lipoproteins, three different concentrations (10, 20 and 40 mg/kg) were used. The results showed that all concentrations of S3 reduced cholesterol, LDL, very-low-density lipoprotein (VLDL) and TG, and increased HDL in rabbits. The level of TG in the hypercholesterolemic group increased significantly compared to other groups (P<0.001). The groups received atorvastatin derivatives showed a significant decrease in TG level compared to the control and hyperlipidemic groups. The 10-mg/kg dose of S3 showed a similar effect in reducing LDL compared to the standard drug. The 20-mg/kg dose of S3 reduced LDL level to the level of the control group. Treatment with 20-mg/kg and 40-mg/kg S3 significantly reduced SGOT and SGPT levels compared to the hyperlipidemic group (P<0.001). The SGPT level increased in the group received atorvastatin, while it showed a significant decrease in the group received S3 at a concentration of 40 mg/kg compared to the control group. A significant decrease in the amount of ALP was observed in the hyperlipidemic group compared to other groups (P<0.001). The values of urea, creatinine and uric acid in the hyperlipidemic group were significantly increased compared to the control group (P<0.001). Treatment with 10 mg/kg S3 significantly reduced the amount of urea, creatinine, and uric acid compared to the hyperlipidemic group (P<0.001).
According to the findings, the control group had normal liver cells and there was no fatty degeneration. The HFD group showed significant liver tissue changes. Compared to the control group, the hypercholesterolemic group had lost the nucleus and membrane. Diet with high cholesterol caused damage to liver cells in the form of fatty destruction in central venous areas. Atorvastatin and S3 groups (10 and 20 mg/kg) had mild fatty degeneration. Fatty degeneration in these groups was less than in the HFD group. Treatment with compound S3 (40 mg/kg) for 30 days reduced the fatty degeneration of hepatocytes compared to the hypercholesterolemic group. The kidney tissue of control group was normal in terms of cortex and medulla. In the group received atorvastatin, the structure of kidney tissue in the cortex was normal. In the medulla, most of the points were normal, and destruction and lysis of the thick Henle wall and collecting tubules were observed in about 10%. In the 10-mg/kg S3 group, the disturbances in the medulla were greatly reduced and reached a normal state. The 40-mg/kg S3 group had the same severity of disorders as the 20-mg/kg S3 group. However, the injuries in these groups were less than the HFD group.
Conclusion
The S3 compound of atorvastatin may be a potent anti-hypercholesterolemia agent. This indicates that phenyl rings with higher electron density attached to propargyl show better inhibitory effects. The S3 compound can be an effective drug in preventing atherosclerosis. However, more study should be conducted to elucidate the exact mechanism.
Ethical Considerations
Compliance with ethical guidelines
In this study, all animal experiments were in accordance to the guidelines of the Ethics Committee of Islamic Azad University, Najafabad Branch (Code: IR.IAU.NAJAFABAD.REC.1398.125).
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors .
Authors contributions
The authors contributed equally to preparing this article.
Conflicts of interest
The authors declared no conflicts of interest.
Acknowledgements
The authors would like to thank Ali Nouri and Hajer Sirous for their efforts in this project.

 
Type of Study: Original Article | Subject: بیوشیمی بالینی-عمومی
Received: 2023/04/14 | Accepted: 2023/06/6 | Published: 2023/08/1

References
1. Han JB, Shu QH, Zhang YF, Yi YX. Predictive value of inflammation biomarkers in patients with portal vein thrombosis. J Clin Transl Hepatol. 2021; 9(3):384-91. [DOI:10.1038/s41366-018-0020-6] [PMID] [PMCID] [DOI:10.1038/s41366-018-0020-6]
2. Alarcon G, Roco J, Medina M, Medina A, Peral M, Jerez S. High fat diet-induced metabolically obese and normal weight rabbit model shows early vascular dysfunction: Mechanisms involved. Int J Obes. 2018; 42(9):1535-43. [DOI:10.1038/s41366-018-0020-6] [PMID] [DOI:10.1038/s41366-018-0020-6]
3. Bonaterra GA, Bender K, Wilhelm B, Schwarzbach H, Metz S, Kelber O, et al. Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits. BMC Cardiovasc Disord. 2020; 20(1):420. [DOI:10.1186/s12872-020-01703-x] [PMID] [DOI:10.1186/s12872-020-01703-x]
4. Dong J, Yang S, Zhuang Q, Sun J, Wei P, Zhao X, et al. The associations of lipid profiles with cardiovascular diseases and death in a 10-year prospective cohort study. Front Cardiovasc Med. 2021; 8:745539. [DOI:10.3389/fcvm.2021.745539] [PMID] [DOI:10.3389/fcvm.2021.745539]
5. Gesto DS, Pereira CMS, Cerqueira NMFS, Sousa SF. An atomic-level perspective of HMG-CoA-reductase: The target enzyme to treat hypercholesterolemia. Molecules. 2020; 25(17):3891. [DOI:10.3390/molecules25173891] [PMID] [DOI:10.3390/molecules25173891]
6. Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: The EASY-FIT study. J Am Coll Cardiol. 2014; 64(21):2207-17. [DOI:10.1016/j.jacc.2014.08.045] [PMID] [DOI:10.1016/j.jacc.2014.08.045]
7. Schonewille M, de Boer JF, Mele L, Wolters H, Bloks VW, Wolters JC, et al. Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. J Lipid Res. 2016; 57(8):1455-64. [DOI:10.1194/jlr.M067488] [PMID] [DOI:10.1194/jlr.M067488]
8. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010; 19(4):393-402. [DOI:10.1097/MNH.0b013e32833aa4ac] [PMID] [DOI:10.1097/MNH.0b013e32833aa4ac]
9. Heravi MM, Zadsirjan V, Saedi P, Momeni T. Applications of friedel-crafts reactions in total synthesis of natural products. RSC Adv. 2018; 8(70):40061-3. [DOI:10.1039/C8RA07325B] [PMID] [DOI:10.1039/C8RA07325B]
10. Vernon H, Wehrle CJ, Sampson K. Alia V, Kasi A. Anatomy, abdomen and pelvis: Liver. Treasure Island: StatPearls Publishing; 2022. [Link]
11. Vogel AI, Furniss BS, Smith PW, Tatchell AR. Vogel's textbook of practical organic chemistry, including qualitative organic analysis. Wilmington: Longman; 1986. [Link]
12. Lu M, Lu Q, Zhang Y, Tian G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res. 2011; 25(4):266-73. [DOI:10.1016/S1674-8301(11)60036-5] [PMID] [DOI:10.1016/S1674-8301(11)60036-5]
13. Kaneva AM, Potolitsyna NN, Bojko ER, Odland JØ. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity. Dis Markers. 2015; 2015:591454.[DOI:10.1155/2015/591454] [PMID] [DOI:10.1155/2015/591454]
14. Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: Distinguishing between particle concentration, type, and content. JAMA Cardiol. 2022; 7(3):250-6. [DOI:10.1001/jamacardio.2021.5083] [PMID] [DOI:10.1001/jamacardio.2021.5083]
15. Zhan X, Chen Y, Yan C, Liu S, Deng L, Yang Y, et al. Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids Health Dis. 2018; 17(1):117. [DOI:10.1186/s12944-018-0771-z] [PMID] [DOI:10.1186/s12944-018-0771-z]
16. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. CMAJ. 2005; 172(3):367-79. [DOI:10.1503/cmaj.1040752] [PMID] [DOI:10.1503/cmaj.1040752]
17. Jeong WI, Jeong DH, Do SH, Kim YK, Park HY, Kwon OD, et al. Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats. J Vet Med Sci. 2005; 67(3):235-42. [DOI:10.1292/jvms.67.235] [PMID] [DOI:10.1292/jvms.67.235]
18. Basaranoglu M, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease: Clinical features and pathogenesis. Gastroenterol Hepatol. 2006; 2(4):282-91. [PMID] [PMCID]
19. Abo-Zalam HB, El-Denshary ES, Abdelsalam RM, Khalil IA, Khattab MM, Hamzawy MA. Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study. Biomed Pharmacother. 2021; 139:111494. [DOI:10.1016/j.biopha.2021.111494] [PMID] [DOI:10.1016/j.biopha.2021.111494]
20. Gao M, Ma Y, Liu D. High-fat diet-induced adiposity, adipose inflammation, hepatic steatosis and hyperinsulinemia in outbred CD-1 mice. Plos One. 2015; 10(3):e0119784. [DOI:10.1371/journal.pone.0119784] [PMID] [DOI:10.1371/journal.pone.0119784]
21. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000; 11(4):669-83. [DOI:10.1681/ASN.V114669] [PMID] [DOI:10.1681/ASN.V114669]
22. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997; 12(9):1908-15. [DOI:10.1093/ndt/12.9.1908] [PMID] [DOI:10.1093/ndt/12.9.1908]
23. Li C, Lim SW, Choi BS, Lee SH, Cha JH, Kim IS, et al. Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol. 2005; 25(6):611-20. [DOI:10.1159/000089905] [PMID] [DOI:10.1159/000089905]
24. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol. 2004; 286(1):F46-57. [DOI:10.1152/ajprenal.00428.2002] [PMID] [DOI:10.1152/ajprenal.00428.2002]
25. Sun BK, Li C, Lim SW, Choi BS, Lee SH, Kim IS, et al. Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity. Nephron Exp Nephrol. 2005; 99(1):e9-16. [DOI:10.1159/000081793] [PMID] [DOI:10.1159/000081793]
26. Declèves AE, Zolkipli Z, Satriano J, Wang L, Nakayama T, Rogac M, et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 2014; 85(3):611-23. [DOI:10.1038/ki.2013.462] [PMID] [DOI:10.1038/ki.2013.462]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Qom University of Medical Sciences Journal

Designed & Developed by : Yektaweb